How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,145 results for

Headache in Pregnancy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Interest of Auriculotherapy in Prophylaxis of Migraine and Headache in Patients With Migraines

: Recruiting First Posted : January 30, 2017 Last Update Posted : November 1, 2018 See Sponsor: Hopital Foch Information provided by (Responsible Party): Hopital Foch Study Details Study Description Go to Brief Summary: The aim of the study is to show that auriculotherapy decreases the number of days with painful episodes of migraine and headache after 3 months of treatment Condition or disease Intervention/treatment Phase Headache, Migraine Procedure: Auriculotherapy Not Applicable Detailed Description (...) 3 sessions of auriculotherapy at one month intervals. No Intervention: AUR-: No auriculotherapy Patients do not benefit from auriculotherapy. Outcome Measures Go to Primary Outcome Measures : Number of days with migraine and non-migraine headache post inclusion. [ Time Frame: 3 months ] Evaluated with the patient's migraine/headache/treatment diary of the last 3 months after inclusion. One day with painful episodes of migraines and non-migraines headaches is a day when: the pain episode lasts

2017 Clinical Trials

82. Botulinum Toxin Type A Block of the Otic Ganglion in Chronic Cluster Headache: Safety Issues

: February 28, 2017 Last Update Posted : May 1, 2018 See Sponsor: Norwegian University of Science and Technology Collaborator: St. Olavs Hospital Information provided by (Responsible Party): Norwegian University of Science and Technology Study Details Study Description Go to Brief Summary: Cluster headache (CH) is the most common of the trigeminal autonomic cephalalgias and one of the most severe pains known to man, having a large impact on the sufferer's quality of life. A parasympathetic dysfunction (...) in CH has been suggested. The sphenopalatine ganglion has been a target for treatment of primary headache disorders for more than a century but there are several anatomic and physiologic studies that suggest that another cranial parasympathetic ganglion, the otic ganglion (OG), might be also relevant in CH. In this study OG will be blocked with botulinum toxin type A in a pilot study in 10 patients with chronic cluster headache. Recruitment of patients will be solely in Norway. There is no data

2017 Clinical Trials

83. A Randomized Study Evaluating the Incidence of Post Lumbar Puncture Headache With Atraumatic Needles in Hematology

score ≥4) will be reported. Secondary Outcome Measures : Intensity of headache [ Time Frame: 5 days ] Maximum intensity of headache as evaluated by verbal rating scale (scoring from 0 to 10) within 5 days following lumbar puncture will be reported for each patient. Duration of significant headache [ Time Frame: 5 days ] Duration in days of mild and severe headache (verbal rating scale score ≥ 4) within 5 days following lumbar puncture will be reported for each patient. Pain intensity [ Time Frame: 5 (...) Statement: Plan to Share IPD: No Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Institut de Cancérologie de la Loire: Lumbar puncture Post lumbar puncture headache Atraumatic needle Haematology Additional relevant MeSH terms: Layout table for MeSH terms Headache Post-Dural Puncture Headache Pain Neurologic Manifestations Signs and Symptoms Headache Disorders, Secondary Headache Disorders Brain

2017 Clinical Trials

84. Acupuncture for Patients With Chronic Tension-type Headache

: Not suffering tension-type headache during the pervious 3 months; Taking any prophylactic headache medication during the previous one month; Headache due to organic disorders (e.g. subarachnoid hemorrhage, cerebral hemorrhage, cerebral embolism, cerebral thrombosis, vascular malformation, arthritis, hypertension, arteriosclerosis); Having serious diseases of the heart, liver, kidney or other organs; In pregnancy or lactation, or planning to be pregnant in 6 months; In unconsciousness, or having psychosis (...) superficially by the depth of 1-3 mm, and the needles will be retained for 30 minutes without any manipulation. Outcome Measures Go to Primary Outcome Measures : Responder rate [ Time Frame: 16 weeks after randomization ] The responder rate is defined as >50% reduction in the number of headache days per four week Secondary Outcome Measures : The number of days with headache [ Time Frame: at baseline before randomization, 4, 8, 12, 16, 20, 24, 28 and 32 weeks after randomization ] The mean pain intensity

2017 Clinical Trials

85. Pretreatment With Sumatriptan on Cilostazol Induced Headache in Healthy Volunteers

to 60 Years (Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Healthy subjects of both sexes Age 18-60 years Weight 50-95 kg. Females were requested to use effective contraception. Exclusion Criteria: Any type of headache (except episodic tension-type headache < 1 day per week) Serious somatic or psychiatric disease Pregnancy Intake of daily medication (except oral contraceptives). Contacts and Locations Go to Information from the National Library (...) . FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Migraine Disorders Headache Headache Disorders, Primary Headache Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Pain Neurologic Manifestations Signs and Symptoms Cilostazol Sumatriptan Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Asthmatic Agents Respiratory System Agents Fibrinolytic Agents Fibrin Modulating

2017 Clinical Trials

86. Sphenopalatine Ganglion Block Versus Occiptal Nerve Block in Treatment of Post Dural Puncture Headache

the dural puncture with a distinct postural quality. PDPH causes significant short-term disability, prevents ambulation and care of the newborn (in obstetrics), and results in a prolonged hospital stay. Condition or disease Intervention/treatment Phase Headache Procedure: Sphenopalatine block Procedure: Greater occipital nerve block Not Applicable Detailed Description: The sphenopalatine ganglion (SPG) is an extra-cranial neural structure located in the pterygopalatine fossa that has both sympathetic (...) of the occipital region). Procedure: Greater occipital nerve block patients will receive bilateral greater occipital nerve block using a mixture of 3ml of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each side of the occipital region). Other Name: GONB Outcome Measures Go to Primary Outcome Measures : Numeric rating pain score [ Time Frame: from intervention up to 24 hours ] pain score Secondary Outcome Measures : Numeric rating pain score for headache. [ Time Frame: from intervention up to 24 hours ] pain

2017 Clinical Trials

87. Mechanical Diagnosis and Therapy vs Traditional Physical Therapy in the Treatment of Mechanical Headaches

of treatment. The MDT method focuses on actively involving the patient in education and self-management of pain. The focus is to have the patient learn about his/her condition and how to manage the symptoms independently when possible. With regards to research that has been conducted on the use of MDT with headaches, one study compared mechanical traction, rhythmic impulse, and MDT exercises in relieving tension-type headaches (TTH). Mechanical cervical traction was found to be more effective at reducing (...) % of adults worldwide, and the pain can have a detrimental effect on an individual's livelihood. In a two-week time period, 12.7% of the US workforce was unable to productively work due to pain, with headache pain as the most common complaint. For those with headache pain, this resulted in 3.5 +/- 0.1 hours of productivity lost in a week. Quality of life, financial situation, employment, and social involvement are negatively impacted by headache pain. Coworkers and family may have to handle work

2017 Clinical Trials

88. Sphenopalatine Ganglion Nerve Block for Postdural Puncture Headache in Obstetrics

: Washington University School of Medicine Information provided by (Responsible Party): Washington University School of Medicine Study Details Study Description Go to Brief Summary: During labor and delivery, pregnant women may choose to receive pain relief called epidural analgesia, which is the delivery of a numbing agent through the back and into a body space around the spinal column. This numbs the area of the stomach and the pelvis. Typically the numbing agent is lidocaine, which is a local anesthetic (...) like your dentist uses. Some times the numbing agent is combined with another medication that causes drowsiness and relieves pain called a narcotic. One of the risks associated with having this kind of pain relief is unintentional puncture of a sheath of tissue that surrounds and protects the spinal cord when inserting the needle. This sheath is called the dura. This would cause the fluid surrounding the spinal cord to leak out and this would cause a headache. This headache is called a post-dural

2017 Clinical Trials

89. Intravenous Fluids in Benign Headaches Trail

and availability for benign headaches is prochlorperazine. Given that IVF administration is a common part of treatment regimen for benign headache patients in the emergency department and given the lack of randomized trials in adults, the investigators aim to study the use of IVF on pain reduction in headache patients in the adult ED. There has been one randomized trial in pediatrics that shows IVF may help in patients with migraines, whereas the adult literature has no randomized control trials and a review (...) of data shows that fluids do not help relieve pain in migraine headache patients. This study will include both adult and pediatric patients presenting to the Emergency Department with complaint of benign headache. Condition or disease Intervention/treatment Phase Headache Drug: Normal Saline 5mL Drug: Normal Saline 20mL/kg Drug: Prochlorperazine 0.15 mg/kg up to 10 mg IV Drug: Diphenhydramine 1 mg/kg up to 50 mg IV Phase 4 Detailed Description: This will be a single center, prospective, single blinded

2017 Clinical Trials

90. Yoga for Pediatric Tension-Type Headache

for Headache Disorders criteria, be between 13 and 18 years old (inclusive), English-speaking, and willing to be randomized and attend yoga sessions regularly. Exclusion Criteria: Participants will be excluded if they have any injury, disease, or metabolic dysfunction known to influence pain, have any physical limitations deemed by a medical practitioner to preclude yoga practice, had attended yoga classes in the previous 3 months, are currently pregnant, or have a history of drug or alcohol dependence (...) Study Details Study Description Go to Brief Summary: This study will determine the efficacy of an 8-week Hatha yoga intervention for adolescents with tension-type headache (TTH) and will assess theoretically-driven mediators of treatment response, including experimental pain sensitivity, chronic stress, and negative cognitions linked to chronic pain. Condition or disease Intervention/treatment Phase Headache Behavioral: Hatha yoga Not Applicable Study Design Go to Layout table for study information

2017 Clinical Trials

91. Headache Inducing Effect of Cromakalim in Migraine Patients

Headache Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Pain Neurologic Manifestations Signs and Symptoms Cromakalim Antihypertensive Agents Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Asthmatic Agents Respiratory System Agents Parasympatholytics Vasodilator Agents (...) Headache Inducing Effect of Cromakalim in Migraine Patients Headache Inducing Effect of Cromakalim in Migraine Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Headache Inducing Effect of Cromakalim

2017 Clinical Trials

92. EFFECTS OF MIOFASCIAL RELEASE AND PERCUTANEOUS MICROELETROLYSIS IN TYPE HEADACHE

, 2017 Last Update Posted : July 21, 2017 See Sponsor: Rodrigo Marcel Valentim da Silva Information provided by (Responsible Party): Rodrigo Marcel Valentim da Silva, Estácio Ponta Negra Study Details Study Description Go to Brief Summary: A headache is a more common disorder and one that prevails over a lifetime of much of the population. Among the causes are in the stress and spasms of the pericranial musculature, presence of painful sensitivity in the region, decrease of pain threshold (...) : Layout table for MeSH terms Headache Tension-Type Headache Pain Neurologic Manifestations Signs and Symptoms Headache Disorders, Primary Headache Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases

2017 Clinical Trials

93. Ketamine v. Ketorolac for Management of Generalized Tension Type Headache

, confusion, agitation, delirium, dreams) during study period, incidence of nausea, vomiting, or worsening headache, Incidence of bad taste, Incidence of burning sensations in the nostrils, incidence of hypertension, time to patient discharge from the initiation of study medication/placebo, patient satisfaction of pain control based on a Likert Scale. Condition or disease Intervention/treatment Phase Migraine Drug: Intravenous ketamine Drug: Ketorolac Drug: Normal saline Phase 4 Detailed Description (...) of the following no nausea/vomiting No more than one of photophobia or phonophobia Exclusion Criteria: Non migraine primary headache disorder or unclassifiable, previous enrollment in study, fever >100.3, Patients with suspected secondary headache disorder such as SAH or sinusitis, performance of lumbar puncture or potential need for LP, Severe hypertension (≥180/100), History of CAD or hypertension, presence of/suspected for traumatic head injury in the past 30 days with or without loss of consciousness

2017 Clinical Trials

94. Treatment of Chronic Migraine Headaches.

to any components of De-Novo formula Presence or known anatomic craniofacial deformities or severe spondylosis/spondylolisthesis of cervical spine, profound dental caries, Maxillofacial deformities Pregnancy and current breast feeding status Headaches attribute to acute head and neck injuries, chronicity of cervicogenic headaches Skin infection or micro abscesses dermatogen or dental, ongoing treatment for Methicillin Resistant Streptococcus Aureus ( MRSA) unless treatment completed. Contacts (...) .: Migraine Craniofacial Neuralgia Additional relevant MeSH terms: Layout table for MeSH terms Migraine Disorders Headache Migraine without Aura Migraine with Aura Headache Disorders, Primary Headache Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Pain Neurologic Manifestations Signs and Symptoms Dexamethasone Dexamethasone acetate Lidocaine BB 1101 Thiamine Anti-Inflammatory Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects

2017 Clinical Trials

95. CGRP's Cluster Headache Inducing Abilities in Cluster Headache Patients

: Layout table for MeSH terms Headache Cluster Headache Pain Neurologic Manifestations Signs and Symptoms Trigeminal Autonomic Cephalalgias Headache Disorders, Primary Headache Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Calcitonin Salmon calcitonin Katacalcin Calcitonin Gene-Related Peptide Calcium-Regulating Hormones and Agents Physiological Effects of Drugs Bone Density Conservation Agents Vasodilator Agents (...) in remission minimum of 1 month remission time fertile women must use safe contraception Exclusion Criteria: All other primary types of headache headache 8 hours or less before study day begins pregnant or lactating women any history or clinical sigs of hyper/hypotension, heart disease, mental disorder, substance abuse, or other illness deemed relevant by the medical doctor assessing the patient Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study

2015 Clinical Trials

96. Pregnancy and Renal Disease

to the survey, including 76 (49%) nephrologists, 36 (23%) obstetricians, 16 (10%) pharmacists, 12 (8%) midwives, 7 (4%) obstetric physicians, 5 (3%) physicians, 2 (1%) patients, 1 dietician and 1 person with role in guideline development. Of those completing the survey, 57 (37%) were part of a specialist multidisciplinary team managing women with CKD in pregnancy and 72 (46%) were routinely involved in either the renal or obstetric care of pregnant women with CKD. The strength of the recommendation (...) guidelines 19 6. Lay summary 74 7. Acknowledgements 75 Appendix 1. The experience of pregnancy and renal disease……………………………………………………………………………….76 Appendix 2. Summary of clinical responsibility for elements of the guideline 80 Appendix 3. Ovid Medline search terms (1946 to 2018) 81 Renal Association Clinical Practice Guideline Pregnancy and Renal Disease – September 2019 4 1. Introduction 1. Background Chronic kidney disease (CKD) is estimated to affect 3% of pregnant women in high-income countries

2019 Renal Association

97. Covid-19: Recommendations for GDM screening and oral glucose tolerance test (OGTT) during pregnancy and postpartum

Covid-19: Recommendations for GDM screening and oral glucose tolerance test (OGTT) during pregnancy and postpartum Translating evidence into best clinical practice Queensland Health NOTICE OF UPDATE DURING COVID-19 PANDEMIC DATE 14 April 2020 TOPIC Recommendations for GDM screening and oral glucose tolerance test (OGTT) during pregnancy and postpartum APPLIES TO All pregnant and postnatal women irrespective of COVID-19 status RATIONALE During the COVID-19 pandemic • Supports social distancing (...) macrosomia (birth weight > 4500 g or > 90th percentile • Previous perinatal loss • Polycystic ovarian syndrome • Medications (corticosteroids, antipsychotics) • Multiple pregnancy COVID-19 pandemic • Applies to: Pregnant women regardless of COVID-19 status • Rationale: To support social distancing and minimise blood collection time (i.e not based on new evidence) • Implementation: Commence as practical and convenient. Seek expert advice as clinically appropriate Check fasting FBG • At 24–28 weeks

2020 Queensland Health

98. Physical Activity and Exercise During Pregnancy and the Postpartum Period

in the forces across joints and the spine during weight-bearing exercise. As a result, more than 60% of all pregnant women experience low back pain . Strengthening abdominal and back muscles could minimize this risk. Blood volume, heart rate, stroke volume, and cardiac output normally increase during pregnancy, and systemic vascular resistance decreases . These hemodynamic changes establish the circulatory reserve necessary to sustain the pregnant woman and fetus at rest and during exercise. Maintaining (...) as a woman can carry on a conversation while exercising, she likely is not overexerting herself . Women should be advised to remain well hydrated, avoid long periods of lying flat on their backs, and stop exercising if they have any of the warning signs listed in . Box 3. Warning Signs to Discontinue Exercise While Pregnant Vaginal bleeding Abdominal pain Regular painful contractions Amniotic fluid leakage Dyspnea before exertion Dizziness Headache Chest pain Muscle weakness affecting balance Calf pain

2020 American College of Obstetricians and Gynecologists

99. Stratification of clinical risk in pregnancy

in medical care may reduce pregnancy risks and have made birth safer than ever before in terms of decreased maternal mortality. However, advances in medicine have also added to the high risk population (e.g. IVF) and the demand on resources, further increasing both clinical and operational risk. Stratification of pregnant women into normal, medium and high-risk categories is arbitrary and made difficult when there is a dearth of information, inappropriate analysis or incomparable processes and procedures (...) . It may be unclear whether the presence of a single risk factor is enough to necessitate a high- risk pregnancy carestream or if a multifactorial/combined risk factor algorithm is more appropriate. This is complicated by the fact that pregnancy covers up to 42 weeks of changes and a lifetime of predisposing factors, potentially contributing to risk. Despite the complexity of stratifying a pregnant woman based on risk, healthcare professionals need to give guidance, based on evidence

2020 National Clinical Guidelines (Ireland)

100. Acute headache diagnosis in pregnant women: A hospital-based study. Full Text available with Trip Pro

Acute headache diagnosis in pregnant women: A hospital-based study. To characterize demographic and clinical features in pregnant women presenting with acute headache, and to identify clinical features associated with secondary headache.We conducted a 5-year, single-center, retrospective study of consecutive pregnant women presenting to acute care with headache receiving neurologic consultation.The 140 women had a mean age of 29 ± 6.4 years and often presented in the third trimester (56.4 (...) ), fever (8.2% vs 0.0%, p = 0.014), and an abnormal neurologic examination (34.7% vs 16.5%, p = 0.014). In multivariate logistic regression, elevated blood pressure (odds ratio [OR] 17.0, 95% confidence interval [CI] 4.2-56.0) and a lack of headache history (OR 4.9, 95% CI 1.7-14.5) had an increased association with secondary headache, while psychiatric comorbidity (OR 0.13, 95% CI 0.021-0.78) and phonophobia (OR 0.29, 95% CI 0.09-0.91) had a reduced association with secondary headache.Among pregnant

2015 Neurology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>